LitAlert ~~ GeneLit.com

    • All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    • Wu HL, Luo ZY, He ZL, Gong Y, Mo M, Ming WK, Liu GY.
    • Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111-y. Epub ahead of print.

    • Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
    • Vertechy L, Boccia SM, Tiberi G, Avesani G, Corrado G, Fagotti A, Scambia G, Marchetti C.
    • Int J Gynecol Cancer. 2022 Dec 23:ijgc-2022-003764. doi: 10.1136/ijgc-2022-003764. Epub ahead of print.

    • Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment.
    • Jackson LM, Moldovan GL.
    • NAR Cancer. 2022 Dec 22;4(4):zcac042. doi: 10.1093/narcan/zcac042.

    • Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment.
    • Wang C, Gao P, Xu J, Liu S, Tian W, Liu J, Zhou L.
    • Front Pharmacol. 2022 Dec 7;13:1078303. doi: 10.3389/fphar.2022.1078303.

    • December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad.
    • Matulonis U, O'Malley D.
    • Gynecol Oncol. Podcasts. 2022 Dec.

    Related:

    •• Original research:

    Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.

    • Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
    • Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL.
    • Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.11.003. Epub ahead of print.